Laninamivir Octanoate
This inhaled prodrug is converted in lung tissue to laninamivir, a long-acting neuraminidase inhibitor that blocks influenza viruses from spreading between cells. A single dose is intended to provide treatment for influenza, making it potentially more convenient than multi-day treatment regimens.
Peso molecular
472,5000 g/mol
LogP
0,40
TPSA
196,00 Ų
Regla de cinco de Lipinski
Cumple
Áreas terapéuticas
Mecanismo de acción
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Estructura 2D
Cite this structure
Embed this structure
SMILES
CCCCCCCC(=O)OC[C@@H](O)[C@@H](OC)[C@@H]1OC(C(=O)O)=C[C@H](NC(=N)N)[C@H]1NC(C)=O
InChI
InChI=1S/C21H36N4O8/c1-4-5-6-7-8-9-16(28)32-11-14(27)18(31-3)19-17(24-12(2)26)13(25-21(22)23)10-15(33-19)20(29)30/h10,13-14,17-19,27H,4-9,11H2,1-3H3,(H,24,26)(H,29,30)(H4,22,23,25)/t13-,14+,17+,18+,19+/m0/s1
Molecular Formula
C21H36N4O8
HBD / HBA
5 / 9
Enlaces Rotables
15
Átomos Pesados
33
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Preguntas frecuentes
This inhaled prodrug is converted in lung tissue to laninamivir, a long-acting neuraminidase inhibitor that blocks influenza viruses from spreading between cells. A single dose is intended to provide treatment for influenza, making it potentially more convenient than multi-day treatment regimens.
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Yes, Laninamivir Octanoate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL467058. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 9847629. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="laninamivir-octanoate"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/laninamivir-octanoate/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/laninamivir-octanoate/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/laninamivir-octanoate/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="laninamivir-octanoate"></drugfyi-drug>